Phase II Trial of Double Dose of Icotinib in Treating Brain Metastases From Non-small Cell Lung Cancer
Status:
Unknown status
Trial end date:
2015-09-01
Target enrollment:
Participant gender:
Summary
Brain metastases, a common complication,occur in 25-40% of patients with non-small cell lung
cancer (NSCLC). Whole-brain radiation therapy(WBRT) and Stereotactic Radiosurgery (SRS) are
important approaches to the treatment of brain metastases from NSCLC. Known to us, epidermal
growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) can pass through the
blood-brain barrier and show promising antitumor activity against brain metastases from
NSCLC, especially for EGFR mutation patients. However, due to the lower concentration of
tyrosine kinase inhibitors (TKIs) in the cerebrospinal fluid and its inevitable emergence of
drug resistance, brain metastases will be refractory or resistant to standard-dose EGFR
inhibitors. Icotinib is one agent of EGFR-TKIs. The previous studies have shown that the
Icotinib conventional dose (125mg, TID) is far from reached its maximum tolerable dose. It is
a challenge whether the further dose escalation of Icotinib will enhance its concentration in
cerebrospinal fluid and thereby improve its therapeutic effect. Here the investigators
examine the therapeutic effect and side-effect of double dose of Icitinib in treating
patients with brain metastases from NSCLC who have suffered from the failure of conventional
dose treatment.